Literature DB >> 25668557

Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial.

Bertrand Souweine1, Alexandre Lautrette, Didier Gruson, Emmanuel Canet, Kada Klouche, Laurent Argaud, Julien Bohe, Maïté Garrouste-Orgeas, Christophe Mariat, François Vincent, Sophie Cayot, Olivier Cointault, Alain Lepape, Dominique Guelon, Michael Darmon, Aurélien Vesin, Nicolas Caillot, Carole Schwebel, Alexandre Boyer, Elie Azoulay, Lila Bouadma, Jean-François Timsit.   

Abstract

RATIONALE: Ethanol rapidly eradicated experimental biofilm. Clinical studies of ethanol lock to prevent catheter-related infections (CRIs) suggest preventive efficacy. No such studies have been done in intensive care units (ICU).
OBJECTIVES: To determine whether ethanol lock decreases the risk of major CRI in patients with short-term dialysis catheters (DCs).
METHODS: A randomized, double-blind, placebo-controlled trial was performed in 16 ICUs in seven university hospitals and one general hospital in France between June 2009 and December 2011. Adults with insertion of a nontunneled, nonantimicrobial-impregnated double-lumen DC for an expected duration greater than 48 hours, to perform renal-replacement therapy or plasma exchange, were randomly allocated (1:1) to receive a 2-minute catheter lock with either 60% wt/wt ethanol solution (ethanol group) or 0.9% saline solution (control group) at the end of DC insertion and after each renal-replacement therapy or plasma exchange session. The main outcome was major CRI defined as either catheter-related clinical sepsis without bloodstream infection or catheter-related bloodstream infection during the ICU stay.
MEASUREMENTS AND MAIN RESULTS: The intent-to-treat analysis included 1,460 patients (2,172 catheters, 12,944 catheter-days, and 8,442 study locks). Median DC duration was 4 days (interquartile range, 2-8) and was similar in both groups. Major CRI incidence did not differ between the ethanol and control groups (3.83 vs. 2.64 per 1,000 catheter-days, respectively; hazard ratio, 1.55; 95% confidence interval, 0.83-2.87; P = 0.17). No significant differences occurred for catheter colonization (P = 0.57) or catheter-related bloodstream infection (P = 0.99).
CONCLUSIONS: A 2-minute ethanol lock does not decrease the frequency of infection of DCs in ICU patients. Clinical trial registered with www.clinicaltrials.gov (NCT 00875069).

Entities:  

Keywords:  catheter-related infection; dialysis catheter; ethanol; prevention; renal-replacement therapy

Mesh:

Substances:

Year:  2015        PMID: 25668557     DOI: 10.1164/rccm.201408-1431OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  What's new: prevention of acute dialysis catheter-related infection.

Authors:  Antoine Schneider; Ian Baldwin; Bertrand Souweine
Journal:  Intensive Care Med       Date:  2017-05-18       Impact factor: 17.440

2.  Understanding biofilm formation in intravascular device-related infections.

Authors:  Christophe Beloin; Nuria Fernández-Hidalgo; David Lebeaux
Journal:  Intensive Care Med       Date:  2016-08-06       Impact factor: 17.440

3.  Obesity and risk of catheter-related infections in the ICU. A post hoc analysis of four large randomized controlled trials.

Authors:  Niccolò Buetti; Bertrand Souweine; Leonard Mermel; Olivier Mimoz; Stéphane Ruckly; Ambre Loiodice; Nicolas Mongardon; Jean-Christophe Lucet; Jean-Jacques Parienti; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2021-02-01       Impact factor: 17.440

Review 4.  Ethanol lock is effective on reducing the incidence of tunneled catheter-related bloodstream infections in hemodialysis patients: a systematic review and meta-analysis.

Authors:  Tingting Zhao; Hong Liu; Jibin Han
Journal:  Int Urol Nephrol       Date:  2018-04-17       Impact factor: 2.370

Review 5.  Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis.

Authors:  Beatriz M Almeida; Daniel H Moreno; Vladimir Vasconcelos; Daniel G Cacione
Journal:  Cochrane Database Syst Rev       Date:  2022-04-01

Review 6.  A state of the art review on optimal practices to prevent, recognize, and manage complications associated with intravascular devices in the critically ill.

Authors:  Jean-François Timsit; Mark Rupp; Emilio Bouza; Vineet Chopra; Tarja Kärpänen; Kevin Laupland; Thiago Lisboa; Leonard Mermel; Olivier Mimoz; Jean-Jacques Parienti; Garyphalia Poulakou; Bertrand Souweine; Walter Zingg
Journal:  Intensive Care Med       Date:  2018-05-12       Impact factor: 17.440

7.  Guidewire exchange vs new site placement for temporary dialysis catheter insertion in ICU patients: is there a greater risk of colonization or dysfunction?

Authors:  Elisabeth Coupez; Jean-François Timsit; Stéphane Ruckly; Carole Schwebel; Didier Gruson; Emmanuel Canet; Kada Klouche; Laurent Argaud; Julien Bohe; Maïté Garrouste-Orgeas; Christophe Mariat; François Vincent; Sophie Cayot; Olivier Cointault; Alain Lepape; Michael Darmon; Alexandre Boyer; Elie Azoulay; Lila Bouadma; Alexandre Lautrette; Bertrand Souweine
Journal:  Crit Care       Date:  2016-07-30       Impact factor: 9.097

Review 8.  Anti-biofilm Activity as a Health Issue.

Authors:  Sylvie Miquel; Rosyne Lagrafeuille; Bertrand Souweine; Christiane Forestier
Journal:  Front Microbiol       Date:  2016-04-26       Impact factor: 5.640

Review 9.  Prevention of catheter-related bloodstream infections in patients on hemodialysis: challenges and management strategies.

Authors:  Vivek Soi; Carol L Moore; Lalathakasha Kumbar; Jerry Yee
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-04-18

10.  Compatibility of Injectable Anticoagulant Agents in Ethanol; In Vitro Antibiofilm Activity and Impact on Polyurethane Catheters of Enoxaparin 400 U/mL in 40% v/v Ethanol.

Authors:  Damien Balestrino; Mercédès Quintana; Nicolas Charbonnel; Christiane Forestier; Claire Lartigue; Bertrand Souweine
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.